Personalized Medicine Group

The Unicancer Personalized Medicine Group develops multidrug predictors to enable the selection of the most effective treatments for individual patients.

President: Prof. Fabrice ANDRÉ, Gustave Roussy, Villejuif

 

 

Strategic priorities

This multidisciplinary group of experts in biology-driven medicine develops programmes aimed at:

  • Providing proofs of concept for personalized treatments,
  • Identifying predictors of sensitivity or resistance to therapy,
  • Identifying biomarkers of relapse or extreme responses,
  • Validating therapeutic decision algorithms based on biological tests.

Cross-pathology trials are developed in close collaboration with several tumour-specific groups in France.

 

 

Contact

Marta Jimenez, Personalized Medicine and Early Trials Programmes Head

Please email us for more information